Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients.

The 5th annual report of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) summarizes and analyzes the first 6 years of patient and data collection. The current analysis includes more than 6000 patients and updated risk factors for continuous flow pumps. Among continuous flow pumps, actuarial survival is 80% at 1 year and 70% at 2 years. Quality of life indicators are generally favorable and adverse event burden will likely influence patient selections of advanced heart failure therapies.

[1]  L. Stevenson,et al.  Third INTERMACS Annual Report: the evolution of destination therapy in the United States. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  Karen Ulisney,et al.  INTERMACS profiles of advanced heart failure: the current picture. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  Karen Ulisney,et al.  INTERMACS database for durable devices for circulatory support: first annual report. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Robert L Kormos,et al.  The Fourth INTERMACS Annual Report: 4,000 implants and counting. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.